Cerebrolysin 10ml is a medication made from purified pig brain protein in the form of an injection or infusion solution that does not contain proteins, lipids, or other antigenic compounds. Cerebrolysin is indicated for use in cases of memory disorders, dementia due to degeneration, stroke, etc. To ensure effective treatment and avoid side effects, users must follow the doctor's instructions.
1. What is the effect of Cerebrolysin 10ml?
What is Cerebrolysin 10ml? Cerebrolysin 10ml is a peptide produced by enzymatic cleavage based on standardized biotechnology. Cerebrolysin is made from purified pig brain protein, in the form of an injection or infusion solution that does not contain proteins, lipids, or other antigenic compounds. Cerebrolysin is packaged in injection vials with a volume of 5ml or 10ml. Each ml of solution contains 215.2mg of Cerebrolysin peptide concentrate and 2.1mg of sodium hydroxide.
Cerebrolysin is effective in treating the following conditions:
- Memory disorders
- Concentration disorders
- Dementia due to degeneration, including Alzheimer's disease
- Dementia due to cerebrovascular disease, multiple infarctions
- Dementia due to both degeneration and vascular causes
- Stroke: ischemic and hemorrhagic
- After trauma and surgery, after contusions, arterial concussions, or after neurosurgery.
2. How to use Cerebrolysin 10ml
Cerebrolysin 10ml is formulated as an injection solution with a concentration of 10ml. It can be administered intramuscularly with a dose of 5ml, and if the dose is greater than 5ml, it can be administered intravenously or by infusion.
The dosage of the medication will depend on the patient's condition and age. Typically, the doctor will prescribe Cerebrolysin injections once a day, with a treatment course lasting a minimum of 10-20 days. For mild cases, a dose of 1-5ml may be used, while severe cases may require 10-30ml. The duration of the treatment course and the dosage depend on the patient's age and the severity of the condition, with the treatment usually lasting about 3-4 weeks. The treatment course can be repeated several times depending on the patient's clinical response, with breaks between treatment courses. In severe cases, patients should not stop the medication abruptly but should continue treatment by injecting the medication once every 2 days for a period of 4 weeks. Based on clinical trials, the usual dose for dementia patients is 5-30ml/24 hours, and for patients after a hemorrhagic stroke or traumatic brain injury, the dose is 10-60ml/24 hours.
Cerebrolysin can be mixed with saline or 5% glucose solution, Ringer's lactate solution, or dextran 40, with a minimum infusion rate of 20-60 minutes. To use the medication safely, inject or infuse Cerebrolysin according to the doctor's instructions, and do not use an overdose, underdose, or for a longer duration than prescribed.
3. Unwanted side effects when using Cerebrolysin 10ml
Cerebrolysin can cause some unwanted side effects such as:
- Swelling and pain at the injection site
- A feeling of warmth at the injection site if injected too quickly
- Tremors
- Headache
- Mild fever
Before prescribing the medication, doctors always consider the benefits and effectiveness of Cerebrolysin. When using Cerebrolysin, unwanted side effects can still occur. Therefore, if there are any abnormal symptoms, especially severe allergic reactions with accompanying signs such as severe dizziness, difficulty breathing, rash, anxiety, cognitive decline, respiratory failure, and coma, the patient should immediately inform the doctor or nurse for immediate medical intervention.
4. Some precautions when using Cerebrolysin 10ml
Some precautions when using Cerebrolysin include:
- Informing the doctor of any history of allergies to Cerebrolysin or hypersensitivity reactions to any other allergens. Cerebrolysin may contain inactive ingredients that can cause allergic reactions or other serious problems.
- Contraindicated for use in patients with epilepsy or prolonged seizures, patients with increased seizure frequency, severe renal failure, etc.
- For pregnant and breastfeeding women, animal studies have not shown any evidence of teratogenic effects, but due to the lack of clinical data in humans, it is necessary to consult a doctor before using the medication.
5. Drug interactions
Drug interactions can reduce the effectiveness of Cerebrolysin or increase the impact of unwanted side effects. Inform your doctor about all other medications you are using, including over-the-counter drugs, vitamins, prescription medications, and herbal products. Do not start, stop, or change the dosage of any medication without your doctor's approval.
Some medications that may interact with Cerebrolysin include:
- Antidepressants
- MAO inhibitors: phenelzine, isocarboxazid, tranylcypromine, etc.
6. How to store Cerebrolysin 10ml?
Cerebrolysin should be stored at room temperature below 30°C, in a dry place away from light. Do not store Cerebrolysin in damp places or in the freezer, and keep it away from heat sources and flames. When the medication has expired or is damaged and cannot be used, healthcare personnel should dispose of it properly. Do not dispose of Cerebrolysin in the environment, such as down the drain or toilet, unless instructed to do so. Consult with waste disposal companies or pharmacists on how to safely dispose of Cerebrolysin to help protect the environment.
In summary, Cerebrolysin is effective in treating memory disorders, concentration disorders, dementia due to degeneration including Alzheimer's disease, dementia due to cerebrovascular disease, multiple infarctions, or dementia due to both degeneration and vascular causes. However, Cerebrolysin can cause some unwanted side effects and drug interactions, so inform your doctor about all medications you are using to reduce the risk of unwanted side effects and increase the effectiveness of the treatment.
To arrange an appointment, please call HOTLINE or make your reservation directly HERE. You may also download the MyVinmec app to schedule appointments faster and manage your reservations more conveniently.
